Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
 - EconoTimes)
NEW ORLEANS, La., March 10, 2017 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until March 27, 2017 to file lead plaintiff applications in a securities class action lawsuit against Mallinckrodt Public Limited Company (NYSE:MNK), if they purchased the Company’s securities between November 25, 2014 and January 18, 2017, inclusive (the “Class Period”). The action is pending in United States District Court for the District of Columbia.
What You May Do
If you purchased securities of Mallinckrodt and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 27, 2017.
About the Lawsuit
The complaint alleges that, throughout the Class Period, Mallinckrodt and its CEO, Mark Trudeau, made a series of false and misleading statements and failed to disclose material adverse facts about the long-term sustainability of Mallinckrodt’s revenues for HP Acthar Gel (“Acthar”), the only FDA-approved adrenocorticotropic hormone preparation. The action alleges that Acthar’s monopoly status was the product of unlawful anticompetitive practices and failed to disclose that its increasing reliance on Medicare and Medicaid meant that Mallinckrodt’s monopolistic Acthar revenue would be threatened if the government took action to limit the price paid for this drug by taxpayers.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
